• Explore /
  • Poster
  • / Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.

Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.

Abstract Video & Slides Poster

Authors

null

Leo Mascarenhas

Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA

Leo Mascarenhas , Cornelis Martinus van Tilburg , Francois Doz , C. Michel Zwaan , Catherine M. Albert , Claudia Blattman , Birgit Geoerger , Steven G. DuBois , Noah Federman , Ramamoorthy Nagasubramanian , Alberto S. Pappo , Tanya Carens Watt , Ricarda Norenberg , Marc Mardoche Fellous , Esther A. De La Cuesta , Theodore Willis Laetsch , Rui-hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT02576431, NCT02637687

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10030)

DOI

10.1200/JCO.2022.40.16_suppl.10030

Abstract #

10030

Poster Bd #

245

Abstract Disclosures

Similar Posters

First Author: Alexander E. Drilon

First Author: David S. Hong

First Author: Maria E. Cabanillas

First Author: Sébastien Perreault